Avan J. Armaghani, MD, surveys the host of research on metastatic breast cancer (mBC) to be presented at this year's ASCO conference, ranging from trials already established in their later stages to more recently launched lines of investigation.
The accumulating data represent the pledge of an expanded therapeutic space, Dr Armaghani implies, one in which agents formerly used against one cancer subtype may potentially extend to others, translating into an enriched array of options in the treatment of MBC.
Medscape © 2022 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: ASCO 2022: Fresh Data in the Setting of Metastatic Breast Cancer Treatment - Medscape - Jun 03, 2022.
Comments